Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Non-initiation of hepatitis C virus antiviral therapy in patients with human immunodeficiency virus/hepatitis C virus co-infection.

Oramasionwu CU, Kashuba AD, Napravnik S, Wohl DA, Mao L, Adimora AA.

World J Hepatol. 2016 Mar 8;8(7):368-75. doi: 10.4254/wjh.v8.i7.368.

2.

Psychosocial issues in patients with chronic hepatitis B and C.

Enescu A, Mitrut P, Balasoiu M, Turculeanu A, Enescu AS.

Curr Health Sci J. 2014 Apr-Jun;40(2):93-6. doi: 10.12865/CHSJ.40.02.02. Epub 2014 Mar 29. Review.

3.

Variation between Canadian centres in the uptake of treatment for hepatitis C by patients coinfected with HIV: a prospective cohort study.

Young J, Potter M, Cox J, Cooper C, Gill J, Hull M, Walmsley S, Klein MB.

CMAJ Open. 2013 Sep 24;1(3):E106-14. doi: 10.9778/cmajo.20130009. eCollection 2013 Sep.

4.

Barriers to hepatitis C antiviral therapy in HIV/HCV co-infected patients in the United States: a review.

Oramasionwu CU, Moore HN, Toliver JC.

AIDS Patient Care STDS. 2014 May;28(5):228-39. doi: 10.1089/apc.2014.0033. Epub 2014 Apr 16. Review.

5.

The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.

Afdhal NH, Zeuzem S, Schooley RT, Thomas DL, Ward JW, Litwin AH, Razavi H, Castera L, Poynard T, Muir A, Mehta SH, Dee L, Graham C, Church DR, Talal AH, Sulkowski MS, Jacobson IM; New Paradigm of HCV Therapy Meeting Participants.

J Viral Hepat. 2013 Nov;20(11):745-60. doi: 10.1111/jvh.12173. Review.

6.

Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA.

Grint D, Peters L, Schwarze-Zander C, Beniowski M, Pradier C, Battegay M, Jevtovic D, Soriano V, Lundgren JD, Rockstroh JK, Kirk O, Mocroft A; EuroSIDA in EuroCoord.

HIV Med. 2013 Nov;14(10):614-23. doi: 10.1111/hiv.12068. Epub 2013 Jul 19.

7.

Influence of healthcare-associated factors on the efficacy of hepatitis C therapy.

Daw MA, Dau AA, Agnan MM.

ScientificWorldJournal. 2012;2012:580216. doi: 10.1100/2012/580216. Epub 2012 Dec 27.

8.

Unhealthy alcohol use, HIV infection and risk of liver fibrosis in drug users with hepatitis C.

Muga R, Sanvisens A, Fuster D, Tor J, Martínez E, Pérez-Hoyos S, Muñoz A.

PLoS One. 2012;7(10):e46810. doi: 10.1371/journal.pone.0046810. Epub 2012 Oct 9.

9.

The risk of hepatocellular carcinoma among individuals with acquired immunodeficiency syndrome in the United States.

Sahasrabuddhe VV, Shiels MS, McGlynn KA, Engels EA.

Cancer. 2012 Dec 15;118(24):6226-33. doi: 10.1002/cncr.27694. Epub 2012 Jun 26.

10.

Provider and patient correlates of provider decisions to recommend HCV treatment to HIV co-infected patients.

Wagner G, Osilla KC, Garnett J, Ghosh-Dastidar B, Bhatti L, Witt M, Goetz MB.

J Int Assoc Physicians AIDS Care (Chic). 2012 Jul-Aug;11(4):245-51. doi: 10.1177/1545109712444163. Epub 2012 May 7.

11.

Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France).

Salmon-Ceron D, Cohen J, Winnock M, Roux P, Sadr FB, Rosenthal E, Martin IP, Loko MA, Mora M, Sogni P, Spire B, Dabis F, Carrieri MP; HEPAVIH group.

BMC Health Serv Res. 2012 Mar 12;12:59. doi: 10.1186/1472-6963-12-59.

12.

Patient Characteristics Associated with HCV Treatment Adherence, Treatment Completion, and Sustained Virologic Response in HIV Coinfected Patients.

Wagner G, Chan Osilla K, Garnett J, Ghosh-Dastidar B, Bhatti L, Goetz MB, Witt M.

AIDS Res Treat. 2011;2011:903480. doi: 10.1155/2011/903480. Epub 2011 Oct 26.

13.

Barriers to receiving hepatitis C treatment for people who inject drugs: Myths and evidence.

Higgs P, Sacks-Davis R, Gold J, Hellard M.

Hepat Mon. 2011 Jul;11(7):513-8.

14.

Patient and provider characteristics associated with the decision of HIV coinfected patients to start hepatitis C treatment.

Osilla KC, Wagner G, Garnett J, Ghosh-Dastidar B, Witt M, Bhatti L, Goetz MB.

AIDS Patient Care STDS. 2011 Sep;25(9):533-8. doi: 10.1089/apc.2011.0048. Epub 2011 Aug 8.

15.

Psychiatric care of the patient with hepatitis C: a review of the literature.

Rifai MA, Gleason OC, Sabouni D.

Prim Care Companion J Clin Psychiatry. 2010;12(6). pii: PCC.09r00877. doi: 10.4088/PCC.09r00877whi.

16.

Treatment for hepatitis C virus genotype 1 infection in HIV-infected individuals on methadone maintenance therapy.

Taylor LE, Bowman SE, Chapman S, Zaller N, Stein MD, Cioe PA, Maynard MA, McGovern BH.

Drug Alcohol Depend. 2011 Jul 1;116(1-3):233-7. doi: 10.1016/j.drugalcdep.2010.11.016. Epub 2010 Dec 21.

17.

The beginning of a new era in understanding hepatitis C virus prevention.

Rich JD, Taylor LE.

J Infect Dis. 2010 Oct 1;202(7):981-3. doi: 10.1086/656213. No abstract available.

18.

Equitable access to HCV care in HIV-HCV co-infection can be achieved despite barriers to health care provision.

Cooper CL, Giordano C, Mackie D, Mills EJ.

Ther Clin Risk Manag. 2010 Apr 26;6:207-12.

19.

Factors that influence an HIV coinfected patient's decision to start hepatitis C treatment.

Osilla KC, Ryan G, Bhatti L, Goetz M, Witt M, Wagner G.

AIDS Patient Care STDS. 2009 Dec;23(12):993-9. doi: 10.1089/apc.2009.0153.

20.

Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study.

Grebely J, Petoumenos K, Matthews GV, Haber P, Marks P, Lloyd AR, Kaldor JM, Dore GJ, Hellard M; ATAHC Study Group.

Drug Alcohol Depend. 2010 Mar 1;107(2-3):244-9. doi: 10.1016/j.drugalcdep.2009.09.015.

Supplemental Content

Support Center